Aceminib is more effective and safer for patients with chronic phase CML

Aximini has demonstrated higher efficacy and safety in the treatment of patients with chronic phase chronic myeloid leukemia (CML). As the first BCR::ABL1 inhibitor targeting the ABLmyristoyl pocket(STAMP), Asiminib’s efficacy has been fully verified in clinical trials. Especially in the ASCEMBL study on patients with CML who had previously received ≥2 tyrosine kinase inhibitors (TKIs), Ascemini showed significant efficacy. Over several years of follow-up, the rate of major molecular response (MMR) in the aximinib group continued to be higher than that in the comparator bosutinib group. For example, at 96 weeks, the MMR rate reached 37.6% in the aximinib group, while it was only 15.8% in the bosutinib group. This data fully illustrates the high effectiveness of aceminib in treating patients with chronic phase CML.

In addition to its remarkable efficacy, Aceminib also demonstrates a good safety profile. Aceminib has a relatively lower incidence of side effects than traditional TKIs, allowing patients to better tolerate the treatment. In the ASCEMBL study, compared with bosutinib, patients in the aximinib group had significantly fewer side effects such as diarrhea, which further proved the safety of aximinib.

In addition to its efficacy and safety, Aceminib can significantly improve patients' quality of life. In related clinical trials, patients treated with aximini reported that theirCMLsymptoms and impact on health-related quality of life remained stable or even improved during treatment. In particular, the severity of common symptoms such as fatigue is reduced, allowing patients to better carry out their daily lives and work.